Company: SCLXW
Filing Date: 2025-09-29
Form Type: 424B3
Source: 0001193125-25-221020
Chunk: 124

Company: Scilex Holding Co
Filing Date: 2025-09-29
Form: 424B3
Chunk 124
---
 forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date

Page | 4

subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements.

Contacts:

Investors and Media

Scilex Holding Company

960 San Antonio Road

Palo Alto, CA 94303

Office: (650) 516-4310

Email: investorrelations@scilexholding.com

Website: www.scilexholding.com

# # #

SEMDEXA (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA
is planned.

ZTlido is a registered trademark owned by Scilex Pharmaceuticals Inc., a
wholly-owned subsidiary of Scilex Holding Company.

Gloperba is the subject of an
exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB is a registered trademark owned by Scilex Holding Company.

Scilex Bio is a trademark owned by Scilex Holding Company, Inc.

All other trademarks are the property of their respective owners.

2025 Scilex Holding Company All Rights Reserved.

Page | 5

Exhibit 99.2

FOR IMMEDIATE RELEASE

September 26, 2025

Scilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI

PALO ALTO, CALIFORNIA – September 26, 2025 (GLOBE NEWSWIRE) - Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq:
SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and
cardiometabolic disease, today announced that it has closed the initial tranche of its previously announced $150 million Bitcoin (BTC) investment in Datavault AI Inc. (Nasdaq: DVLT, “Datavault”), pursuant to which Scilex is expected
to receive up to an aggregate of 278,914,094 shares of Datavault common stock (at an effective purchase price of $0.5378 per share) (subject to adjustment for stock splits and similar transactions). At the closing of this initial tranche, Scilex